Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Express Scripts
Deloitte
Medtronic
Fuji
Chubb
Merck
Farmers Insurance
Federal Trade Commission

Generated: July 17, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,078,412

« Back to Dashboard

Summary for Patent: 7,078,412
Title:Quinuclidine derivatives and medicinal compositions containing the same
Abstract: The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2] octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds.
Inventor(s): Fernandez Forner; Maria Dolors (Barcelona, ES), Prat Quinones; Maria (Barcelona, ES), Buil Albero; Maria Antonia (Barcelona, ES)
Assignee: Almirall Prodesfarma AG (Baar, CH)
Application Number:11/116,777
Patent Claims: 1. A compound which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2] octane wherein an anion X.sup.- is associated with the positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

2. The compound according to claim 1 which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1- azoniabicyclo[2.2.2] octane bromide.

3. A pharmaceutical composition comprising a compound according to claim 1 in admixture with a pharmaceutically acceptable carrier or diluent.

4. The pharmaceutical composition of claim 3 comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3 -phenoxypropyl)-1-azoniabicyclo[2.2.2] octane bromide.

5. The pharmaceutical composition according to claim 3 further comprising a .beta..sub.2 agonist.

6. The pharmaceutical composition according to claim 4 further comprising a .beta..sub.2 agonist.

7. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of a compound according to claim 1.

8. The method according to claim 7 comprising administering to the patient an effective amount of 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2] octane bromide.

9. The method according to claim 7 further comprising administering to the patient an effective amount of a .beta..sub.2 agonists.

10. The method according to claim 8 further comprising administering to the patient an effective amount of a .beta..sub.2 agonist.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Daiichi Sankyo
Healthtrust
Harvard Business School
Julphar
Federal Trade Commission
Chubb
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.